Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2019
This article has no abstract
Epistemonikos ID: 298da232e0608dc40f62ba1753b72cafb2733dc2
First added on: Feb 11, 2025